1. Biosimilar erythropoiesis‐stimulating agents are an effective and safe option for the management of myelofibrosis‐related anemia. (16th December 2022) Authors: Inzoli, Elena; Crisà, Elena; Pugliese, Novella; Civettini, Ivan; Lanzarone, Giuseppe; Castelli, Andrea; Martinelli, Vincenzo; Montelisciani, Laura; Antolini, Laura; Gambacorti‐Passerini, Carlo; Elli, Elena Maria Journal: European journal of haematology Issue: Volume 110:Number 4(2023) Page Start: 354 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients. Issue 3 (24th March 2023) Authors: Malighetti, Federica; Arosio, Giulia; Manfroni, Chiara; Mauri, Mario; Villa, Matteo; Manghisi, Beatrice; Inzoli, Elena; Rindone, Giovanni; Zambrotta, Giovanni P. M.; Civettini, Ivan; Guglielmana, Veronica; Ramazzotti, Daniele; Giudici, Giovanni; Bombelli, Silvia; Perego, Roberto; Piazza, Rocco; M... Journal: HemaSphere Issue: Volume 7:Issue 3(2023) Page Start: e852 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success. Issue 8 (12th April 2022) Authors: Inzoli, Elena; Aroldi, Andrea; Piazza, Rocco; Gambacorti‐Passerini, Carlo Journal: American journal of hematology Issue: Volume 97:Issue 8(2022) Page Start: 1075 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗